Gentile, Marino
 Distribuzione geografica
Continente #
NA - Nord America 527
EU - Europa 341
AS - Asia 83
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 2
Totale 957
Nazione #
US - Stati Uniti d'America 527
SE - Svezia 164
IT - Italia 77
IE - Irlanda 41
SG - Singapore 33
CN - Cina 23
FR - Francia 18
DE - Germania 15
IN - India 13
RU - Federazione Russa 8
HK - Hong Kong 6
AU - Australia 4
CZ - Repubblica Ceca 3
KR - Corea 3
TR - Turchia 3
BE - Belgio 2
CH - Svizzera 2
GB - Regno Unito 2
GR - Grecia 2
UA - Ucraina 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AT - Austria 1
EU - Europa 1
FI - Finlandia 1
IQ - Iraq 1
IR - Iran 1
LT - Lituania 1
NL - Olanda 1
PL - Polonia 1
Totale 957
Città #
Chandler 183
New York 38
Ashburn 36
Dublin 33
Singapore 22
Princeton 21
Milan 17
San Mateo 16
Wilmington 15
Marseille 13
Florence 12
Dearborn 9
Pune 9
Los Angeles 7
Norwalk 7
Trieste 7
Boston 6
Garden City 6
Houston 6
Moscow 6
Fairfield 5
Redwood City 5
Beijing 4
Benalla 4
Bologna 4
Cattolica 4
Hong Kong 4
Redmond 4
Seattle 4
Vicopisano 4
Bremen 3
Falls Church 3
Fremont 3
Genoa 3
Hefei 3
Izmir 3
Jacksonville 3
Seoul 3
Washington 3
Andover 2
Bari 2
Brno 2
Brussels 2
Central 2
Chengdu 2
Chicago 2
Oshkosh 2
Rome 2
Turin 2
Venice 2
Verona 2
Ann Arbor 1
Asti 1
Atlanta 1
Augusta 1
Berlin 1
Bern 1
Boardman 1
Botzingen 1
Brdo 1
Camden 1
Clearwater 1
Ferrara 1
Guidonia Montecelio 1
Gurgaon 1
Helsinki 1
Kish 1
Lausanne 1
Millbury 1
Mountain View 1
Munich 1
Naaldwijk 1
Nanchang 1
Nanjing 1
Naples 1
Pomigliano D'arco 1
Riano 1
Saint Petersburg 1
San Francisco 1
Santarcangelo di Romagna 1
Tianjin 1
Vergiate 1
Vienna 1
Woodbridge 1
Totale 595
Nome #
Adult phenotype in Koolen-de Vries/KANSL1 haploinsufficiency syndrome 87
Evaluation of the performance of Dutch Lipid Clinic Network score in an Italian FH population: The LIPIGEN study 63
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study 58
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases 55
Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs 54
Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study 51
Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death 50
CD49d promotes disease progression in chronic lymphocytic leukemia: New insights from CD49d bimodal expression 44
Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice. 43
Prognostic impact and risk factors of infections in patients with chronic lymphocytic leukemia treated with ibrutinib 43
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials 41
Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study 41
Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies 39
Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group 39
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases 39
Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group 39
Clinical Features of Patients with Cervical Artery Dissection and Fibromuscular Dysplasia 36
Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report 32
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab 32
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus 31
Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: A Campus CLL report 27
Combining PARP inhibition and immune checkpoint blockade in ovarian cancer patients: a new perspective on the horizon? 22
Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL 17
Totale 983
Categoria #
all - tutte 6.214
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.214


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202023 0 0 1 0 5 6 2 2 3 0 4 0
2020/202128 0 0 0 6 0 0 9 0 1 9 1 2
2021/2022233 5 0 49 32 27 5 2 26 7 7 48 25
2022/2023422 58 67 30 64 18 66 15 25 55 3 12 9
2023/2024243 9 59 11 12 15 59 14 12 1 8 14 29
2024/202524 9 13 2 0 0 0 0 0 0 0 0 0
Totale 983